Predicting and Preventing Breast Cancer Resistance to CDK4/6 Inhibitors

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have identified key genetic factors that can predict resistance to CDK4/6 inhibitors, a common treatment for breast cancer. This discovery, published in Nature, offers a new strategy for personalized treatment decisions and has led to a phase 3 clinical trial to test this approach.

Understanding CDK4/6 Inhibitor Resistance

Many patients with breast cancer initially respond well to CDK4/6 inhibitor combinations, but often develop resistance over time. Approximately 10% of patients experience resistance through the loss of the RB1 gene, a protective gene crucial for tumor suppression. The new research focuses on identifying warning signs before treatment begins to anticipate this resistance.

Key Genetic Indicators of Resistance

The study identified two primary indicators that suggest a patient may develop resistance to CDK4/6 inhibitors:

• DNA Repair Problems: Specifically, homologous recombination deficiency (HRD), a condition where cancer cells struggle to repair broken DNA.
• Initial Tumor Genetic Makeup: The presence of certain genetic alterations in the tumor can predict the likelihood of RB1 gene loss.

The Role of BRCA2 Mutations and HRD

The research revealed a link between inherited mutations in the BRCA2 gene and an increased risk of RB1 mutations. Patients with BRCA2 mutations, and those with other genes linked to HRD, are more likely to experience RB1 loss and exhibit poorer responses to CDK4/6 inhibitor-based therapy.

EvoPAR-Breast01 Clinical Trial

Based on these findings, a global, randomized phase 3 clinical trial, EvoPAR-Breast01, is underway. This trial is evaluating whether using PARP inhibitors and hormonal therapy as a first-line treatment for patients with newly diagnosed, HRD-positive metastatic breast cancer is more effective than standard CDK4/6 inhibitor-based therapy.

How PARP Inhibitors May Offer a Solution

Preclinical studies and clinical data suggest that PARP inhibitors may be more effective than CDK4/6 inhibitors in tumors with HRD. Some tumors may develop “reversion mutations” that restore DNA repair function, potentially regaining sensitivity to CDK4/6 inhibitors after initial PARP inhibitor treatment. This suggests a dynamic approach to treatment, potentially utilizing PARP inhibitors early to improve outcomes and preserve future treatment options.

Research Background and Ongoing Efforts

This study builds upon previous research led by Dr. Pedram Razavi, and Dr. Sarat Chandarlapaty at MSK, which has identified multiple mechanisms of CDK4/6 inhibitor resistance, including loss of RB1 function and alterations in the TP53 tumor suppressor gene. The research involved analyzing data from over 5,800 MSK breast cancer patients to understand the impact of both inherited and acquired genetic changes on tumor growth and treatment response.

The Importance of Translational Research and Patient Contribution

The success of this research highlights the importance of translational research – quickly applying scientific discoveries to clinical trials. Dr. Razavi and the MSK team expressed gratitude to the thousands of patients who have participated in MSK’s translational research programs, and specifically acknowledged the contribution of a patient who participated through MSK’s Last Wish Program, providing critical tumor samples for validation of the findings. Collaboration with AstraZeneca was similarly key to advancing the strategy into a phase 3 trial.

Key Takeaways

• Genetic analysis can predict which breast cancer patients are likely to develop resistance to CDK4/6 inhibitors.
• Patients with BRCA2 mutations and HRD are at higher risk of resistance.
• PARP inhibitors may be a more effective first-line treatment option for patients with HRD-positive tumors.
• The EvoPAR-Breast01 trial is testing this new treatment strategy.